Isam Marar, MD
Internal Medicine · Council Bluffs, IANPI 1104976109
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 1,322 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 9.8% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,322 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Amgen$2K
- AstraZeneca$2K
- Novo Nordisk$2K
- AbbVie$1K
- Gilead$1K
- plus $12K from 54 others
Across 714 payments — averaging $2040.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$665K
- Novartis$297K
- Kowa Research Institute, Inc.$203K
- Novo Nordisk AS$160K
- Ionis Pharmaceuticals, Inc.$60K
- Pfizer$25K
- plus $47K from 3 others
What the payments were for
- Food & beverage$21,93696%
- Education$8484%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,783 in reported general payments places this provider in the 95th percentile of 583 internal medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 345 | $402,864 |
| OzempicSemaglutide | 282 | $347,469 |
| FarxigaDapagliflozin Propanediol | 237 | $192,468 |
| JardianceEmpagliflozin | 132 | $128,478 |
| Tresiba Flextouch U-200Insulin Degludec | 94 | $122,673 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 123 | $95,224 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 91 | $77,760 |
| Tresiba Flextouch U-100Insulin Degludec | 98 | $73,559 |
| EliquisApixaban | 73 | $60,907 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 80 | $51,146 |
| XareltoRivaroxaban | 60 | $48,267 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 51 | $47,280 |
| XifaxanRifaximin | 12 | $44,403 |
| TrulicityDulaglutide | 31 | $36,086 |
| MyrbetriqMirabegron | 44 | $33,665 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $2,233 | $438,949376 claims |
| Novo NordiskOzempic, Rybelsus | $1,920 | $374,801307 claims |
| Boehringer IngelheimJardiance, Trijardy Xr, Glyxambi, Tradjenta, Synjardy Xr | $361 | $262,447291 claims |
| AstraZenecaFarxiga, Symbicort | $2,026 | $202,161269 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $623 | $115,685151 claims |
| MerckJanumet Xr, Januvia, Janumet, Belsomra | $691 | $100,432152 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $522 | $77,76091 claims |
| PfizerEliquis | $892 | $60,90773 claims |
| Johnson & JohnsonXarelto | $871 | $48,26760 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $234 | $44,40312 claims |
| Astellas Pharma US IncMyrbetriq | $970 | $33,66544 claims |
| AbbVieLinzess | $1,402 | $25,20936 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 internal medicine providers in Iowa.
Other internal medicine in Council Bluffs
- Alan KricsfeldCouncil Bluffs$49K
- Matthew FryzekCouncil Bluffs$28K
- Diana Rabadi MararCouncil Bluffs$25K
- Barry KricsfeldCouncil Bluffs$13K
- Vikrant SalariaCouncil Bluffs$7K
- Mark JohnsonMason City$223K
- Mark CarlsonSioux City$174K
- Madalyn WalshIowa City$80K
- Aziz HammoudIowa City$29K
- Ali SaeedCedar Rapids$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.